Perceptive Advisors LLC Cuts Position in Cumberland Pharmaceuticals Inc. $CPIX

Posted by Brian Himes on Aug 2nd, 2026

Perceptive Advisors LLC decreased its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX – Free Report) by 42.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,978 shares of the specialty pharmaceutical company’s stock after selling 144,109 shares during the quarter. Perceptive Advisors LLC owned 1.31% of Cumberland Pharmaceuticals worth $640,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of CPIX. Marshall Wace LLP purchased a new position in shares of Cumberland Pharmaceuticals in the fourth quarter valued at $192,000. Bridgeway Capital Management LLC increased its position in Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after purchasing an additional 4,200 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after purchasing an additional 27,980 shares in the last quarter. Geode Capital Management LLC lifted its position in Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after purchasing an additional 5,653 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,326 shares during the last quarter. 15.51% of the stock is owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Price Performance

CPIX stock opened at $6.68 on Friday. The stock has a market cap of $100.07 million, a PE ratio of -13.63 and a beta of 0.09. Cumberland Pharmaceuticals Inc. has a 12 month low of $1.85 and a 12 month high of $8.09. The company has a 50-day moving average price of $6.29 and a 200 day moving average price of $4.72. The company has a current ratio of 0.95, a quick ratio of 0.79 and a debt-to-equity ratio of 0.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). Cumberland Pharmaceuticals had a negative net margin of 17.60% and a negative return on equity of 12.01%. The company had revenue of $9.13 million for the quarter, compared to analyst estimates of $8.50 million.

Cumberland Pharmaceuticals Announces Dividend

The firm also recently declared a dividend, which was paid on Friday, July 31st. Investors of record on Thursday, July 23rd were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Monday, August 3rd.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Analysis on CPIX

Cumberland Pharmaceuticals Profile

(Free Report)

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

Institutional Ownership by Quarter for Cumberland Pharmaceuticals (NASDAQ:CPIX)

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.